(NASDAQ: TKNO) Alpha Teknova's forecast annual revenue growth rate of 6.14% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 2.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 121.37%.
Alpha Teknova's revenue in 2025 is $38,250,000.On average, 1 Wall Street analysts forecast TKNO's revenue for 2025 to be $2,169,696,886, with the lowest TKNO revenue forecast at $2,169,696,886, and the highest TKNO revenue forecast at $2,169,696,886.
In 2026, TKNO is forecast to generate $2,490,341,746 in revenue, with the lowest revenue forecast at $2,490,341,746 and the highest revenue forecast at $2,490,341,746.